These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12359587)

  • 1. t-PA in CRVO.
    Hayreh SS
    Ophthalmology; 2002 Oct; 109(10):1758-61; author reply 1761-3. PubMed ID: 12359587
    [No Abstract]   [Full Text] [Related]  

  • 2. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.
    Weiss JN; Bynoe LA
    Ophthalmology; 2001 Dec; 108(12):2249-57. PubMed ID: 11733266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein.
    Weiss JN
    Am J Ophthalmol; 1998 Jul; 126(1):142-4. PubMed ID: 9683166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone.
    Lahey JM; Kearney JJ; Cheung MC
    Br J Ophthalmol; 2004 Aug; 88(8):1100-1. PubMed ID: 15258039
    [No Abstract]   [Full Text] [Related]  

  • 5. Surgical treatment of central retinal vein occlusion.
    Berker N; Batman C
    Acta Ophthalmol; 2008 May; 86(3):245-52. PubMed ID: 18494725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion.
    Hattenbach LO; Wellermann G; Steinkamp GW; Scharrer I; Koch FH; Ohrloff C
    Ophthalmologica; 1999; 213(6):360-6. PubMed ID: 10567867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 8. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
    Hattenbach LO; Friedrich Arndt C; Lerche R; Scharrer I; Baatz H; Margaron F; Richard G; Behrens-Baumann W; Ohrloff C
    Retina; 2009; 29(7):932-40. PubMed ID: 19584651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion.
    Chen CS; Lee AW; Campbell B; Paine M; Lee T; Fraser C; Grigg J; Markus R; Williams K; Coster DJ
    Int J Stroke; 2011 Feb; 6(1):87-9. PubMed ID: 21205247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous tissue plasminogen activator for acute stroke in California: recipients and resources.
    Birbeck GL; Cui X; Zingmond DS; Vickrey BG
    Cerebrovasc Dis; 2004; 17(4):341-3. PubMed ID: 15103183
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion.
    Hattenbach LO; Steinkamp G; Scharrer I; Ohrloff C
    Ophthalmologica; 1998; 212(6):394-8. PubMed ID: 9787229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of tissue plasminogen activator in silicone oil-filled eyes.
    Kertes PJ; Peyman GA; Chou F; Meffert S; Conway MD
    Can J Ophthalmol; 1998 Feb; 33(1):28-9. PubMed ID: 9513769
    [No Abstract]   [Full Text] [Related]  

  • 13. Concomitant nitroglycerin and rTPA.
    Massel D
    Am Heart J; 1997 Jun; 133(6):713-4. PubMed ID: 9200401
    [No Abstract]   [Full Text] [Related]  

  • 14. Equivalence trials.
    Ware JH; Antman EM
    N Engl J Med; 1997 Oct; 337(16):1159-61. PubMed ID: 9329939
    [No Abstract]   [Full Text] [Related]  

  • 15. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.
    Paques M; Vallée JN; Herbreteau D; Aymart A; Santiago PY; Campinchi-Tardy F; Payen D; Merlan JJ; Gaudric A; Massin P
    Br J Ophthalmol; 2000 Dec; 84(12):1387-91. PubMed ID: 11090479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerated dosing regimen.
    Coplin WM; Broderick J; Tomsick TT
    Neurosurgery; 2001 Jul; 49(1):228-9. PubMed ID: 11440452
    [No Abstract]   [Full Text] [Related]  

  • 17. [Thrombolysis in stroke--results of the ECASS study (European Cooperative Acute Stroke Study)].
    Nervenarzt; 1995 Aug; 66(8 Suppl):1-8. PubMed ID: 9131091
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion.
    Ishida M; Abe S; Nakagawa T; Hayashi A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2135-2140. PubMed ID: 28803326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
    Maiser SJ; Georgiadis AL; Suri MF; Vazquez G; Lakshminarayan K; Qureshi AI
    Int J Stroke; 2011 Feb; 6(1):25-32. PubMed ID: 21205237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous thrombolytic therapy for stroke emergencies.
    Bethel SA
    J Emerg Nurs; 1997 Aug; 23(4):344-6. PubMed ID: 9379578
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.